Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-02-06
2007-02-06
Powers, Fiona T. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S255030, C514S311000, C514S323000, C544S143000, C544S144000, C544S355000, C546S176000, C546S201000
Reexamination Certificate
active
10470359
ABSTRACT:
Disclosed are cannabimimetic aminoalkylindole compounds and methos for their manufacture. The disclosed compounds are surprisingly potent and selective cannabinoinds. Also disclosed are methods of using the disclosed compounds, including use of the disclosed compounds to stimulate a cannabinoid receptor, to provide a physiological effect in an animal or individual and to treat a condition in an animal or individual.
REFERENCES:
patent: 3041343 (1962-06-01), Jucker et al.
patent: 3465024 (1969-09-01), Brownstein et al.
patent: 3573327 (1971-03-01), Miyano
patent: 3577458 (1971-05-01), Brownstein et al.
patent: 3838131 (1971-09-01), Gauthier
patent: 3656906 (1972-04-01), Bullock
patent: 3886184 (1975-05-01), Matsumoto et al.
patent: 3897306 (1975-07-01), VIdic
patent: 3915996 (1975-10-01), Archer
patent: 3928598 (1975-12-01), Archer
patent: 3944673 (1976-03-01), Archer
patent: 3946029 (1976-03-01), Descamps et al.
patent: 3953603 (1976-04-01), Archer
patent: 4036857 (1977-07-01), Razdan et al.
patent: 4054582 (1977-10-01), Blanchard et al.
patent: 4087545 (1978-05-01), Archer et al.
patent: 4087546 (1978-05-01), Archer et al.
patent: 4087547 (1978-05-01), Archer et al.
patent: 4088777 (1978-05-01), Archer et al.
patent: 4102902 (1978-07-01), Archer et al.
patent: 4152450 (1979-05-01), Day et al.
patent: 4171315 (1979-10-01), Ryan
patent: 4176233 (1979-11-01), Archer et al.
patent: 4179517 (1979-12-01), Mechoulam et al.
patent: 4188495 (1980-02-01), Althuis et al.
patent: 4208351 (1980-06-01), Archer et al.
patent: 4278603 (1981-07-01), Thakkar
patent: 4282248 (1981-08-01), Mechoulam et al.
patent: 4382943 (1983-05-01), Winter et al.
patent: 4395560 (1983-07-01), Ryan
patent: 4497827 (1985-02-01), Nelson
patent: 4550214 (1985-10-01), Mehta
patent: 4758597 (1988-07-01), Martin et al.
patent: 4812457 (1989-03-01), Narumiya et al.
patent: 4876276 (1989-10-01), Mechoulam et al.
patent: 4885295 (1989-12-01), Bell
patent: 5053548 (1991-10-01), Tanaka et al.
patent: 5068234 (1991-11-01), D'Ambra et. al.
patent: 5147876 (1992-09-01), Mizuchi et al.
patent: 5223510 (1993-06-01), Gubin et al.
patent: 5284867 (1994-02-01), Kloog et al.
patent: 5324737 (1994-06-01), D'Ambra et al.
patent: 5434295 (1995-07-01), Mechoulam et al.
patent: 5440052 (1995-08-01), Makriyannis et al.
patent: 5462960 (1995-10-01), Barth et al.
patent: 5489580 (1996-02-01), Makriyannis et al.
patent: 5521215 (1996-05-01), Mechoulam et al.
patent: 5532237 (1996-07-01), Gallant et al.
patent: 5538993 (1996-07-01), Mechoulam et al.
patent: 5576436 (1996-11-01), McCabe et al.
patent: 5605906 (1997-02-01), Lau
patent: 5607933 (1997-03-01), D'Ambra et al.
patent: 5618955 (1997-04-01), Mechoulam et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 5635530 (1997-06-01), Mechoulam et al.
patent: 5688825 (1997-11-01), Makriyannis et al.
patent: 5744459 (1998-04-01), Makriyannis et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 5804601 (1998-09-01), Kato et al.
patent: 5817651 (1998-10-01), D'Ambra et al.
patent: 5872148 (1999-02-01), Makriyannis et al.
patent: 5874459 (1999-02-01), Makriyannis et al.
patent: 5925628 (1999-07-01), Lee et al.
patent: 5925768 (1999-07-01), Barth et al.
patent: 5932610 (1999-08-01), Shohami et al.
patent: 5948777 (1999-09-01), Bender et al.
patent: 6013648 (2000-01-01), Rinaldi et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6096740 (2000-08-01), Mechoulam et al.
patent: 6127399 (2000-10-01), Yuan
patent: 6166066 (2000-12-01), Makriyannis et al.
patent: 6284788 (2001-09-01), Mittendorf et al.
patent: 6391909 (2002-05-01), Makriyannis et al.
patent: 6579900 (2003-06-01), Makriyannis et al.
patent: 6610737 (2003-08-01), Garzon et al.
patent: 2002/0119972 (2002-08-01), Leftheris et al.
patent: 2002/0173528 (2002-11-01), Fride et al.
patent: 2003/0120094 (2003-06-01), Makriyannis et al.
patent: 2003/0149082 (2003-08-01), Makriyannis et al.
patent: 2004/0077649 (2004-04-01), Makriyannis et al.
patent: 2004/0077851 (2004-04-01), Makriyannis et al.
patent: 2004/0087590 (2004-05-01), Makriyannis et al.
patent: 0276732 (1988-08-01), None
patent: 0444451 (1991-09-01), None
patent: 0471609 (1993-06-01), None
patent: 0737671 (1996-10-01), None
patent: 0860168 (2001-09-01), None
patent: 2240003 (1975-05-01), None
patent: 2735774 (2001-01-01), None
patent: 2027021 (1980-02-01), None
patent: 57098228 (1982-06-01), None
patent: 2304080 (1990-12-01), None
patent: WO 93/13099 (1993-07-01), None
patent: WO 97/00860 (1997-01-01), None
patent: WO 99/57106 (1999-11-01), None
patent: WO 99/57107 (1999-11-01), None
patent: WO 99/64389 (1999-12-01), None
patent: WO 00/32200 (2000-06-01), None
patent: WO 01/28329 (2001-04-01), None
patent: WO 01/28497 (2001-04-01), None
patent: WO 01/28498 (2001-04-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/29007 (2001-04-01), None
patent: WO 01/32169 (2001-05-01), None
patent: WO 01/58869 (2001-08-01), None
patent: WO 02/058636 (2002-08-01), None
patent: WO 03/005960 (2003-01-01), None
patent: WO 03/020217 (2003-03-01), None
patent: WO 03/035005 (2003-05-01), None
patent: WO 03/063758 (2003-08-01), None
patent: WO 03/064359 (2003-08-01), None
Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A.; “(R)-Methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability”; J. Med. Chem.; 37(12); 1889-1893; 1994; Coden: JMCMAR; ISSN: 0022-2623; XP002040932.
Alo, B.I.; Kandil, A.; Patil, P. A.; Sharp, M. J.; Siddiqui, M. A.; and Snieckus, V. Sequential Directed Ortho Metalation-Boronic Acid Cross-Coupling Reactions. A general Regiospecific Route to Oxygenerated Dibenzo[b,d]pyran-6-ones Related to Ellagic Acid, J. Org. Chem. 1991, 56, 3763-3768.
Arnone M., Maruani J., Chaperon P, et al, Selective inhibition of sucrose and ethanol intake by SR141716, an antagonist of central cannabinoid (CB1) receptors, Psychopharmacal, (1997) 132, 104-106. (abstract only).
Barnett-Norris et al; “Exploration of biologically relevant conformations of anandamide, . . . ”; J. Med. Chem.; vol. 41; 4861-4872; 1998.
Beak, P.; and Brown, R A., The Tertiary Amide as an Effective Director of Ortho Lithiation, J. Org. Chem. 1982, 47, 34-36.
Belgaonkar et al; “synthesius of isocoumarins”; Indian J. Chem; vol. 13; No. 4; 336-338; 1975 (abstract only).
Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D; “Functional Role Of High-Affinity Anandamide Transport, as Revealed By Selective Inhibition”; Science; vol. 277; 1094-1097; 1997.
Berdyshev EV, Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids. Nov. 2000; 108(1-2):169-90.
Berglund et al; “Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: . . . ”; Prostanglandins, leukotrienes ands essential fatty acids; 59(2); 111-118; (1998). (abstract only).
Bodnar, V.N., Lozinskii, M.O., Pel'kis, P.S.; “Synthesis fo 2,5-disubstituted 1,3,4-oxadiazoles and 1,4-dihydro-1,2,4,5-tetrazines”; Ukrainskii Khimicheskii Zhurnal (Russian Edition); 48(12); 1308-1311; 1982 (abstract only).
Bracey, M et al, Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. Science 2002; 298(5599): 1793-1796.
Brenneisen R, Pgli A, Elsohly MA, Henn V. Spiess Y: The effect of orally and rectally administered 9-tetrahydrocannabinol on spasticity, a polit study with 2 patients. Int. J. Clin Pharmacol Ther. (1996) 34:446-452. (abstract only).
Brown et al; “Synthesis and hydroboration of (−)-2-phenylapopinene, Comparison of mono(2-phenylapoisopinocampheyl)borane with its 2-methyl and 2-ethyl analogues for the chiral hydroboration of representative alkenes”; J. Org. Chem.; 55(4); 1217-1223; (1990).
Buckley NE, McCoy KI, Mpzey E et al, “Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor”; Eur. J Pharmacol (2000) 396:141-149.
Burstein et al; “detection of cannabinoid receptors . . . ”; Biochem. Biophys. Res. Commun.;
Deng Hongfeng
Makriyannis Alexandros
Alix Yale & Ristas, LLP
Powers Fiona T.
University of Connecticut
LandOfFree
Receptor selective cannabimimetic aminoalkylindoles does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor selective cannabimimetic aminoalkylindoles, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor selective cannabimimetic aminoalkylindoles will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833779